Chemo-prAIdict Breast: A deep learning solution for predicting residual disease on biopsies of breast cancer patients treated with neoadjuvant chemotherapy

Breast Cancer

Tailoring Treatment to Cancer Risk and Patient Preference: The 2025 St Gallen International Breast Cancer Consensus Statement on Individualizing Therapy for Patients With Early Breast Cancer

Ann Oncol

Burstein HJ, Curigliano G, Gnant M, Loibl S, Regan MM, Loi S, Denkert C, Poortmans P, Cameron D, Thurlimann B, Weber WP, Panelists of the St. Gallen International Breast Cancer Consensus 2025

doi: 10.1016/j.annonc.2025.09.007

SABCS 2025

Breast Cancer

TAXIS (SAKK 23/16): Nodal disease volume, nodal understaging and factors associated with additional nodal disease at ALND in patients with stage II–III breast cancer

Breast Cancer

Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients

J Natl Cancer Inst

Lambertini M, Allegranza D, Laubender RP, Harbeck N, Swain SM, Geyer CE, Slamon DJ, Bobba G, Lambertini C, de Haas S, Restuccia E, Vaz-Luis I, Cameron DA, Krop IE, Winer EP, Anderson RA

doi: 10.1093/jnci/djaf198

Breast Cancer

Real-world progression-free survival and overall survival in patients with HR(+)/HER2(-) advanced breast cancer treated in first-line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study

Int J Cancer

Fasching PA, Brucker C, Decker T, Engel A, Göhler T, Jackisch C, Janssen J, Köhler A, Lüdtke-Heckenkamp K, Lüftner D, Marmé F, van Mackelenbergh M, Rautenberg B, Schmidt M, Weide R, Wimberger P, Kisseleff E, Pfister C, Quiering C, Roos C, Wöckel A

doi: 10.1002/ijc.70397

Breast Cancer

Neoadjuvant endocrine therapy often leads to breast and axilla-conserving surgery in stages II and III hormone receptor-positive breast cancer patients: A registry study

Int J Cancer

Andour L, Kroep JR, Putter H, Tollenaar RAEM, Mesker WE, Straver ME

doi: 10.1002/ijc.70219

Breast Cancer

Chemotherapy duration and patient-reported outcomes in HER2-positive early breast cancer: Results from the TRAIN-3 study

Eur J Cancer

Louis FM, der Voort AV, Egeler MD, Ramshorst MSV, Mandjes IA, Kemper I, Agterof MJ, der Steeg WAV, Heijns JB, Bekkum MLV, Siemerink EJ, Kuijer PM, Scholten A, Wesseling J, Peeters MTV, Mann RM, de Poll-Franse LVV, Sonke GS, Dutch Breast Cancer Research Group (BOOG)

doi: 10.1016/j.ejca.2026.116882

Breast Cancer

Internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer (EORTC trial 22922/10925): an unplanned subset analysis of 20-year outcomes in patients with node-negative breast cancer

Lancet Oncol

Kaidar-Person O, Weltens CG, Fortpied C, Scheijmans LJEE, Kirkove CY, Budach V, Peignaux-Casasnovas K, Valli M, Peters M, van der Leij F, Rivera S, Weidner N, van den Bongard DHJG, Linsenmeier C, Abdah-Bortnyak R, Hosni S, Koiter E, Engelen AM, Baten A, Champezou L, Fourquet A, Bartelink HGMM, Struikmans H, Poortmans PMP, EORTC Radiation Oncology and Breast Cancer Groups

doi: 10.1016/S1470-2045(26)00233-0

ESMO 2025

Breast Cancer

LBA1: DESTINY-Breast05: T-DXd significantly improves IDFS and DFS versus T-DM1 in HER2-positive early breast cancer with residual invasive disease

Breast Cancer

Chemotherapy-Induced Nausea and Vomiting in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy With Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel Versus an Anthracycline-Free Regimen With Docetaxel, Cyclophosphamide-Results From a Randomized Clinical Trial

Int J Cancer

Hörner M, Schäffler H, Häberle L, Goossens C, Pfister K, Leinert E, Veselinovic K, Brucker SY, Köhler U, Heinrich G, Schneeweiss A, Beckmann MW, Fasching PA, Janni W, Rack B, Heublein S, Ziegler P

doi: 10.1002/ijc.70528

Related content

Tailoring Treatment to Cancer Risk and Patient Preference: The 2025 St Gallen International Breast Cancer Consensus Statement on Individualizing Therapy for Patients With Early Breast Cancer

TAXIS (SAKK 23/16): Nodal disease volume, nodal understaging and factors associated with additional nodal disease at ALND in patients with stage II–III breast cancer

Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients

Real-world progression-free survival and overall survival in patients with HR(+)/HER2(-) advanced breast cancer treated in first-line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study

Neoadjuvant endocrine therapy often leads to breast and axilla-conserving surgery in stages II and III hormone receptor-positive breast cancer patients: A registry study

Chemotherapy duration and patient-reported outcomes in HER2-positive early breast cancer: Results from the TRAIN-3 study

Internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer (EORTC trial 22922/10925): an unplanned subset analysis of 20-year outcomes in patients with node-negative breast cancer

LBA1: DESTINY-Breast05: T-DXd significantly improves IDFS and DFS versus T-DM1 in HER2-positive early breast cancer with residual invasive disease

Chemotherapy-Induced Nausea and Vomiting in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy With Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel Versus an Anthracycline-Free Regimen With Docetaxel, Cyclophosphamide-Results From a Randomized Clinical Trial